Not Available

We apologise but the Imperial Brands Science website isn’t available in your geographic location. Please visit our corporate site to find out more about the science we’re undertaking and the innovations we’re exploring.

Our Thoughts

//Laboratory Tests Suggest blu Vapour Does Not Disrupt Endothelial Cell Migration

Posted 09/10/2019 12:00am

By Arran Frood, Scientific Digital Communications Editor


Research by Imperial Brands has contributed to the substantial body of existing literature recognising vaping’s harm reduction potential relative to smoking.

The research, which was presented by study co-author Matthew Stevenson at the annual CORESTA Congress in October 2019, compared the in-vitro impact of cigarette1 smoke and myblu2 vapour on the endothelial cells which line the interior surface of blood and lymphatic vessels.

Previous studies have suggested cigarette smoke can inhibit in-vitro human endothelial cellular migration, resulting in disrupted vascular integrity – with adult smokers more likely to develop health complications relating to vascular disease.

To assess this, our scientists ‘wounded’ human umbilical vein endothelial cells, before exposing them to cigarette smoke and myblu vapour for an extended period.

Notable differences in the rate of wound closure were observed, with the cigarette smoke significantly inhibiting the ‘healing’ of this gap via cell migration. This was in marked contrast to exposure to myblu vapour, which had no notable inhibiting impact and was near identical to the negative control – even at the highest concentrations – under the test conditions.

Kathryn Rudd, In-Vitro Research Toxicologist at Imperial Brands Science, comments:

“Using next-generation in-vitro methodologies, we continue to demonstrate the notable harm reduction potential of our blu e-vapour portfolio relative to conventional cigarettes.

“Our framework – which is based on TT21C methodologies and avoids the need to test on animals – is relevant, ethical and provides valuable data across multiple endpoints.”

Grant O’Connell, Strategic Science & Policy Engagement Director at Imperial Brands, adds:

“blu forms an integral part of our wider Next Generation portfolio of potential harm reduction products. With each new piece of research, our belief that blu offers adult smokers a compelling alternative to conventional cigarettes grows.

“As we continue to establish this robust evidence base, we demand public health bodies, regulators and journalists across the world play their part in promoting tobacco harm reduction by basing their policies, legislation and stories on sound scientific fact rather than extrapolated fiction.”


You are free to share this content with credit to Imperial Brands under a Attribution-NoDerivatives 4.0 International (CC BY-ND 4.0) license.

  1. Kentucky Reference Cigarette (3R4F)
  2. Tobacco flavour; 1.6% nicotine strength
Back to Our Thoughts